News
NEO
8.50
-0.58%
-0.05
NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks · 2d ago
NeoGenomics, Inc. (NASDAQ:NEO) insider upped their holding by 31% earlier this year
Looking at NeoGenomics, Inc.'s ( NASDAQ:NEO ) insider transactions over the last year, we can see that insiders were...
Simply Wall St. · 06/20 11:39
Stocks That Hit 52-Week Lows On Monday
  During Monday's trading, 1214 companies set new 52-week lows.
Benzinga · 06/13 16:18
Top 10 Stock Picks of Andrew Wiener’s Samjo Capital
In this article, we discuss the top 10 stock picks of Andrew Wiener’s Samjo Capital. If you want to skip our detailed analysis of Wiener’s history, investment philosophy, and hedge fund performance, go directly to Top 5 Stock Picks of Andrew Wiener’s Samjo...
Insider Monkey · 06/13 15:13
Analyst Ratings for NeoGenomics
Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over t...
Benzinga · 06/03 16:12
NeoGenomics gets CAP certification for China lab paving way for use as potential trial site
NeoGenomics (NASDAQ:NEO) said it received CAP certification with zero deficiencies paving the way for it to offer its pharmaceutical partners an option to use its Suzhou laboratory for trials relating
Seekingalpha · 06/03 13:25
Piper Sandler Starts NeoGenomics at Overweight With $13 Price Target
MT Newswires · 06/03 05:36
NeoGenomics names interim CEO
NeoGenomics (NASDAQ:NEO) appointed Lynn Tetrault, Esq., current Executive Chair and Principal Executive Officer, as board chair and interim CEO, effective May 12. Ms. Tetrault has been serving as Executive Chair since March
Seekingalpha · 05/16 11:32
NeoGenomics Appoints Lynn Tetrault as Interim CEO and Board Chair
MT Newswires · 05/16 07:56
NeoGenomics Appoints Vishal Sikri as President
MT Newswires · 05/11 17:23
Investors in NeoGenomics (NASDAQ:NEO) have unfortunately lost 76% over the last year
Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...
Simply Wall St. · 05/05 10:53
--Raymond James Adjusts NeoGenomics' Price Target to $15 from $18, Keeps Outperform Rating
MT Newswires · 04/28 14:42
--Raymond James Reduces NeoGenomics Price Target to $15 From $18, Outperform Rating Kept
MT Newswires · 04/28 12:50
NeoGenomics: Q1 Earnings Insights
  NeoGenomics (NASDAQ:NEO) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 04/27 12:55
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 13.04% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/27 12:45
NeoGenomics Q1 EPS $(0.40) Misses $(0.23) Estimate, Sales $117.00M Beat $116.68M Estimate
NeoGenomics (NASDAQ:NEO) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.23) by 73.91 percent. This is a 900 percent decrease over losses of $(0.04) per share from the
Benzinga · 04/27 11:25
NeoGenomics Non-GAAP EPS of -$0.20 beats by $0.04, revenue of $117.17M beats by $0.73M
NeoGenomics press release (NASDAQ:NEO): Q1 Non-GAAP EPS of -$0.20 beats by $0.04. Revenue of $117.17M (+1.4% Y/Y) beats by $0.73M. "While our first quarter performance was disappointing and inconsistent with
Seekingalpha · 04/27 11:08
NeoGenomics Q1 Adjusted Loss Widens, Revenue Rises; Shares Up Pre-Bell
MT Newswires · 04/27 09:07
NeoGenomics Q1 2022 Earnings Preview
NeoGenomics (NASDAQ:NEO) is scheduled to announce Q1 earnings results on Wednesday, April 27th, before market open. The consensus EPS Estimate is -$0.24 and the consensus Revenue Estimate is $116.44M (+0.8% Y/Y).
Seekingalpha · 04/26 18:06
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. is an operator of a network of cancer-focused testing laboratories. The Company’s customers include Clinical and Pharma. Its Clinical customers include community-based pathology practices, oncology groups, hospitals and academic centers. Its Pharma customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The Company' Pharma Services segment provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.